Intercept Pharmaceuticals
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, Intercept Pharmaceuticals sits in the top decile of US sponsors by registered trial count (#801 of 15,742 sponsors by registered trial count).
Intercept Pharmaceuticals: 18 sponsored US clinical trials, 1 recruiting.
Intercept Pharmaceuticals sponsors 18 registered US clinical trials on ClinicalTrials.gov, 1 of them currently recruiting, and 12 completed. 6 of these trials are in Phase 3-4 (later-stage) and 11 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Alcohol-associated Hepatitis, with 1 trials.
Top-decile sponsor footprint
Intercept Pharmaceuticals ranks in the top decile of sponsors by registered trial count (#801 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
12 of 17 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (70.6%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
18 total, page 1 of 1
FXR Effect on Severe Alcohol-Associated Hepatitis (FRESH) Study
NCT05639543
To Evaluate Safety and Tolerability of the Fixed- Dose Combination of Obeticholic Acid and Bezafibrate
NCT06488911
Study of OCA in Combination With BZF Evaluating Efficacy, Safety and Tolerability in Participants With PBC
NCT05239468
Study of Obeticholic Acid (OCA) Evaluating Pharmacokinetics and Safety in Participants With Primary Biliary Cholangitis (PBC) and Hepatic Impairment
NCT03633227
Study Evaluating the Efficacy and Safety of Obeticholic Acid in Subjects With Compensated Cirrhosis Due to Nonalcoholic Steatohepatitis
NCT03439254
Combination Obeticholic Acid (OCA) and Statins for Monitoring of Lipids (CONTROL)
NCT02633956
Randomized Global Phase 3 Study to Evaluate the Impact on NASH With Fibrosis of Obeticholic Acid Treatment
NCT02548351
Real-World Data Study to Evaluate the Effectiveness of OCA on Hepatic Outcomes in PBC Patients
NCT05292872
Obeticholic Acid (OCA) in Primary Sclerosing Cholangitis (PSC)
NCT02177136
Phase 4 Study of Obeticholic Acid Evaluating Clinical Outcomes in Patients With Primary Biliary Cholangitis
NCT02308111
Phase 2 Study on Effects of Obeticholic Acid (OCA) on Lipoprotein Metabolism in Participants With Primary Biliary Cirrhosis
NCT01865812
Single Dose and Multiple Dose Trial to Assess Pharmacokinetics of Obeticholic Acid (OCA)
NCT01933503
Effect of Food on Pharmacokinetics of Obeticholic Acid (OCA)
NCT01914562
Hepatic Impairment Trial of Obeticholic Acid
NCT01904539
Phase 3 Study of Obeticholic Acid in Patients With Primary Biliary Cirrhosis
NCT01473524
Study of INT-747 as Monotherapy in Participants With Primary Biliary Cirrhosis (PBC)
NCT00570765
Study of INT 747 in Combination With URSO in Patients With Primay Biliary Cirrhosis (PBC)
NCT00550862
Study of INT-747 in Patients With Diabetes and Presumed NAFLD
NCT00501592
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 3 |
| Phase 2 | 8 |
| Phase 3 | 4 |
| Phase 4 | 2 |
Therapeutic Areas
What is open in the Intercept Pharmaceuticals pipeline
1 recruiting of 18 indexed (6% open); 12 completed (67%).
Phase mix: 6 late (III/IV) vs 11 early (I/II) (early-phase heavy).
Top condition: Alcohol-associated Hepatitis (1 trial), 0 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Intercept Pharmaceuticals: open-pipeline peers nationwide
Peers matched on 18 registered trials and 6% open enrollment, not the therapeutic-area sidebar.
Intercept Pharmaceuticals sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 18 trials (± recruiting share)
- ADC Therapeutics S.A. · 18 trials · 11% recruiting
- Akros Pharma · 18 trials · 0% recruiting
- AO Clinical Investigation and Publishing Documentation · 18 trials · 0% recruiting
- AO Innovation Translation Center · 18 trials · 33% recruiting
Sponsors near 6% open enrollment (± trial volume)
- Boston College · 6% recruiting · 18 trials
- CytoDyn · 6% recruiting · 18 trials
- Dendreon · 6% recruiting · 18 trials
- NGM Biopharmaceuticals · 6% recruiting · 18 trials
Related
What to do with this Intercept Pharmaceuticals page
18 registered trials is a research-attention snapshot, not an endorsement of Intercept Pharmaceuticals or any single study.
- 1 of Intercept Pharmaceuticals's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Alcohol-associated Hepatitis is the condition Intercept Pharmaceuticals studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Alcohol-associated Hepatitis trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Intercept Pharmaceuticals pipeline card: 18 registered trials from official public datasets.Report a data error.